scholarly journals Reduced glycemic variability and flexible graft function after islet transplantation: A case report

2020 ◽  
Vol 11 (6) ◽  
pp. 1677-1680 ◽  
Author(s):  
Toshihiro Nakamura ◽  
Junji Fujikura ◽  
Takayuki Anazawa ◽  
Ryo Ito ◽  
Masahito Ogura ◽  
...  
Keyword(s):  
Case Report ◽  
Islet Transplantation ◽  
Graft Function ◽  
Glycemic Variability

CGM Shows Islet Transplantation Prevents Hypoglycemia, Correcting Time in Range and Reducing Glycemic Variability, Despite Subnormal Beta-Cell Function

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 143-OR ◽  
Author(s):  
SHAREEN FORBES ◽  
TOLU OLUTOYIN OLATEJU ◽  
ANNA LAM ◽  
JOHN CASEY ◽  
JOHN CAMPBELL ◽  
...  
Keyword(s):  
Beta Cell ◽  
Islet Transplantation ◽  
Beta Cell Function ◽  
Cell Function ◽  
Glycemic Variability ◽  
Time In Range

scholarly journals Implication of Mitochondrial Cytoprotection in Human Islet Isolation and Transplantation

2012 ◽  
Vol 2012 ◽  
pp. 1-16 ◽  
Author(s):  
Yong Wang ◽  
Joshua E. Mendoza-Elias ◽  
Meirigeng Qi ◽  
Tricia A. Harvat ◽  
Sang Joon Ahn ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Islet Transplantation ◽  
Mitochondrial Function ◽  
Graft Function ◽  
Complex Nature ◽  
Islet Isolation ◽  
Success Rates ◽  
Mitochondrial Integrity ◽  
Multistep Process ◽  
Underlying Mechanisms

Islet transplantation is a promising therapy for type 1 diabetes mellitus; however, success rates in achieving both short- and long-term insulin independence are not consistent, due in part to inconsistent islet quality and quantity caused by the complex nature and multistep process of islet isolation and transplantation. Since the introduction of the Edmonton Protocol in 2000, more attention has been placed on preserving mitochondrial function as increasing evidences suggest that impaired mitochondrial integrity can adversely affect clinical outcomes. Some recent studies have demonstrated that it is possible to achieve islet cytoprotection by maintaining mitochondrial function and subsequently to improve islet transplantation outcomes. However, the benefits of mitoprotection in many cases are controversial and the underlying mechanisms are unclear. This article summarizes the recent progress associated with mitochondrial cytoprotection in each step of the islet isolation and transplantation process, as well as islet potency and viability assays based on the measurement of mitochondrial integrity. In addition, we briefly discuss immunosuppression side effects on islet graft function and how transplant site selection affects islet engraftment and clinical outcomes.

Liver focal fatty changes at ultrasound after islet transplantation: an early sign of altered graft function?

2010 ◽  
Vol 27 (8) ◽  
pp. 960-964 ◽  
Author(s):  
M. Venturini ◽  
E. Angeli ◽  
P. Maffi ◽  
C. Losio ◽  
P. Pozzi ◽  
...  
Keyword(s):  
Islet Transplantation ◽  
Graft Function ◽  
Early Sign

scholarly journals Extra-Hepatic Islet Transplantation

2018 ◽  
Vol 27 (8) ◽  
pp. 1289-1293 ◽  
Author(s):  
Anaïs Schaschkow ◽  
Séverine Sigrist ◽  
Carole Mura ◽  
Caroline Dissaux ◽  
Karim Bouzakri ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Cell Therapy ◽  
Islet Transplantation ◽  
Graft Function ◽  
Surgical Techniques ◽  
Diabetic Rats ◽  
C Peptide ◽  
And Function ◽  
Islet Survival

Following the tremendous development of hydrogels for cell therapy, there is now a growing need for surgical techniques to validate in vivo scaffold benefits for islet transplantation. Therefore, we propose a newly designed surgical procedure involving the injection of hydrogel-embedded pancreatic islets in the omentum, which is considered a favorable environment for cell survival and function. Our technique, called h-Omental Matrix Islet filliNG (hOMING) was designed to test the benefits of hydrogel on islet survival and function in vivo. Islets were implanted in the omentum of diabetic rats using the hOMING technique and alginate as an islet carrier. Blood glucose and C-peptide levels were recorded to assess graft function. After 2 months, grafts were explanted and studied using insulin and vessel staining. All rats that underwent hOMING exhibited graft function characterized by a glycemia decrease and a C-peptidemia increase ( P < 0.001 compared with preoperative levels). Furthermore, hOMING appeared to preserve islet morphology and insulin content and allowed the proper revascularization of grafted islets. The results suggest that hOMING is a viable and promising approach to test in vivo the benefits of hydrogel administration for islet transplantation into the omental tissue.

Super-High-Dose Islet Transplantation Is Associated With High SUITO Index and Prolonged Insulin Independence: A Case Report

2010 ◽  
Vol 42 (6) ◽  
pp. 2156-2158 ◽  
Author(s):  
S. Matsumoto ◽  
H. Noguchi ◽  
M. Takita ◽  
M. Shimoda ◽  
Y. Tamura ◽  
...  
Keyword(s):  
Case Report ◽  
Islet Transplantation ◽  
High Dose ◽  
Insulin Independence

scholarly journals Human Recombinant Antithrombin (ATryn®) Administration Improves Survival and Prevents Intravascular Coagulation after Intraportal Islet Transplantation in a Piglet Model

2017 ◽  
Vol 26 (2) ◽  
pp. 309-317 ◽  
Author(s):  
Valery Gmyr ◽  
Caroline Bonner ◽  
Ericka Moerman ◽  
Antoine Tournoys ◽  
Nathalie Delalleau ◽  
...  
Keyword(s):  
Islet Transplantation ◽  
Islet Cells ◽  
Graft Function ◽  
Treated Group ◽  
Pancreatic Tissue ◽  
Control Group ◽  
Physiological Regulation ◽  
Intravascular Coagulation ◽  
Inflammatory Parameters ◽  
Islet Inflammation

Human islet transplantation is a viable treatment option for type 1 diabetes mellitus (T1DM). However, pancreatic islet inflammation after transplantation induced by innate immune responses is likely to hinder graft function. This is mediated by incompatibility between islets and the blood interface, known as instant blood-mediated inflammatory reaction (IBMIR). Herein we hypothesized that portal venous administration of islet cells with human recombinant antithrombin (ATryn®), a serine protease inhibitor (serpin), which plays a central role in the physiological regulation of coagulation and exerts indirect anti-inflammatory activities, may offset coagulation abnormalities such as disseminated intravascular coagulation (DIC) and IBMIR. The current prospective, randomized experiment was conducted using an established preclinical pig model. Three groups were constituted for digested pancreatic tissue transplantation (0.15 ml/kg): control, NaCl 0.9% ( n = 7); gold standard, heparin (25 UI/kg) ( n = 7); and human recombinant ATryn® (500 UI/kg) ( n = 7). Blood samples were collected over time (T0 to 24 h), and biochemical, coagulation, and inflammatory parameters were evaluated. In both the control and heparin groups, one animal died after a portal thrombosis, while no deaths occurred in the ATryn®-treated group. As expected, islet transplantation was associated with an increase in plasma IL-6 or TNF-α levels in all three groups. However, DIC was only observed in the control group, an effect that was suppressed after ATryn® administration. ATryn® administration increased antithrombin activity by 800%, which remained at 200% for the remaining period of the study, without any hemorrhagic complications. These studies suggest that coadministration of ATryn® and pancreatic islets via intraportal transplantation may be a valuable therapeutic approach for DIC without risk for islets and subjects.

Sign in / Sign up

Export Citation Format

Share Document